Humira, Avastin, Herceptin, and Mabthera also saw drug prices cut after entering the market for similar drugs. Domestic sales of Lucentis, an eye disease treatment, fell by more than 30%. As Chong Kun Dang and Samsung Bioepis launched biosimilars, drug prices went down and sales took a direct hit. New drugs from multinational pharmaceutical companies, such as Remicade, Enbrel, Herceptin, Mabthera, Humira, and Avastin, are experiencing repeated sales declines due to drug price cuts after the introduction of domestically developed biosimilars. It is evaluated that a virtuous cycle structure in which domestic companies' R&D achievements generate hundreds of billions of won in health insurance financial savings is being esta